(Q44647368)

English

Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin

scientific article published on January 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

5 December 2017

Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin (English)

1 reference

Europe PubMed Central

5 December 2017

Once‐Daily Niacin Extended Release/Lovastatin Combination Tablet Has More Favorable Effects on Lipoprotein Particle Size and Subclass Distribution Than Atorvastatin and Simvastatin (English)

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Cardiology and cardiovascular medicine

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

author name string

Harold E. Bays

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14605511

30 March 2024

Mark E. McGovern

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14605511

30 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14605511

30 March 2024

publication date

1 January 2003

1 reference

Europe PubMed Central

5 December 2017

full work available at URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1520-037X.2003.03142.x

Portable Document Format

online access status

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14605511

30 March 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1520-037X.2003.03142.x

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1520-037X.2003.03142.x

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Preventive Cardiology

1 reference

Europe PubMed Central

5 December 2017

6

1 reference

Europe PubMed Central

5 December 2017

4

1 reference

Europe PubMed Central

5 December 2017

179-188

1 reference

Europe PubMed Central

5 December 2017

Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2003.03142.X

21 January 2018

LDL subclass phenotypes and the insulin resistance syndrome in women.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1520-037X.2003.03142.X

21 January 2018

Lipoprotein subclasses and atherosclerosis

1

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women.

2

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction

5

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Lipoprotein atherogenicity: an overview of current mechanisms

6

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Plasma high density lipoprotein subfractions in subjects with different coronary risk indices as assessed by plasma lipoprotein concentrations

7

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

High density lipoproteins and coronary atherosclerosis. A strong inverse relation with the largest particles is confined to normotriglyceridemic patients

8

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Lipoprotein heterogeneity: diagnostic and therapeutic implications

10

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Small LDL, atherogenic dyslipidemia, and the metabolic syndrome

12

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

13

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report

15

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

High-density lipoprotein subpopulations in pathologic conditions

16

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Lipoprotein abnormalities related to women's health

17

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Changes in LDL density across the menopausal transition

18

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

LDL subclass phenotypes and triglyceride metabolism in non-insulin-dependent diabetes

19

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density

21

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects

22

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial

25

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Effect of fluvastatin on low-density lipoprotein peak particle diameter.

26

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

28

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

29

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Differential effects of nicotinic acid in subjects with different LDL subclass patterns

31

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Effects of extended-release niacin on lipoprotein subclass distribution

32

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

The benefits of niacin in atherosclerosis

33

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia

34

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Existing and investigational combination drug therapy for high-density lipoprotein cholesterol

35

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

36

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial

37

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial

38

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Comparison of extended-release niacin and atorvastatin monotherapies and combination treatment of the atherogenic lipid profile in diabetes mellitus

39

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

43

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

44

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

45

1 reference

10.1111/J.1520-037X.2003.03142.X

https://api.crossref.org/works/10.1111/J.1520-037X.2003.03142.X

30 March 2024

Identifiers

10.1111/J.1520-037X.2003.03142.X

1 reference

Europe PubMed Central

5 December 2017

1 reference

Europe PubMed Central

5 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44647368&oldid=2114118748"